191546-96-0

Usage

Uses

Used in Pharmaceutical Industry:
1-Oxo Mirtazapine (Mirtazapine Impurity C) is used as a reference standard for the identification, quality control, and quantification of impurities in the synthesis, manufacturing, and testing of Mirtazapine. This helps ensure the safety, efficacy, and purity of the final Mirtazapine product.
Used in Research and Development:
1-Oxo Mirtazapine (Mirtazapine Impurity C) is utilized as a research compound in the study of Mirtazapine's pharmacological properties, mechanism of action, and potential side effects. This aids in the development of new therapeutic strategies and the improvement of existing treatments for major depressive disorder and other related conditions.

Upstream product

• 130277-16-6 2-amino-3-benzylpyridine 
• 1071504-81-8 N-(2-hydroxyethyl)-N-methyl-10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepine-10-carboxamide 
• 1071504-75-0 10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepine-10-carboxylic acid ethyl ester 
• 1071504-70-5 10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepine-10-carboxylic acid methyl ester 
• 1071504-87-4 N-(2-chloro-ethyl)-N-methyl-2-(10,11-dihydro-5H-benzo[e]pyrido[2,3-b]azepin-10-yl)-carboxamide 

Downstream Products

• 85650-52-8 Mirtazapine 

Relevant academic research and scientific papers

A METHOD FOR THE PREPARATION OF AN ENANTIOMERICALLY PURE BENZAZEPINE

The invention relates to a method for the preparation of a cyclic compound according to formula (III) comprising reacting a compound according to Formula (I) and a compound according to formula (II), wherein in Formula (I), R1, R2, R3 and R4 may be hydrogen or substituent groups comprising one or more carbon atoms and/or hetero-atoms, wherein R1, R2, R3 and R4 can be combined in aromatic or aliphatic ring structures, -Y is a ring element comprising 1-3 substituted or unsubstituted carbon atoms and/or heteroatoms in the ring and -R5 is hydrogen or a hydrocarbon substituent group comprising one or more carbon atoms and optionally one or more hetero atoms, and wherein in Formula (II), Z1 and Z2 are, leaving groups, X is a reactive functional hydrocarbon group for subsequent ring closure, comprising one or more carbon atoms and a reactive functional group and having a chain of between 1 to 6 atoms between the carbon atom attached to the central carbon atom of formula (II) and the reactive functional group and R8 is hydrogen or a hydrocarbon substituent different from X making the central carbon atom of formula II a chiral centre in Formula (III) and wherein reactive functional group X can be or can be extended to be compound of formula (IV) which can be ring closed to produce the polycyclic component of formula (V). More in particular, the invention relates to the preparation of mirtazapine precursors and mirtazapine preferably having a substantial enantiomeric excess.

METHOD FOR THE PREPARATION OF AN ENANTIOMERICALLY PURE BENZAZEPINE

The invention relates to a method for the preparation of a cyclic compound according to formula III comprising reacting a compound according to Formula I and a compound according to formula II, wherein in Formula I, R1, R2, R3 and R4 may be hydrogen or substituent groups comprising one or more carbon atoms and/or hetero-atoms, wherein R1, R2, R3 and R4 can be combined in aromatic or aliphatic ring structures, —Y is a ring element comprising 1-3 substituted or unsubstituted carbon atoms and/or heteroatoms in the ring and —R5 is hydrogen or a hydrocarbon substituent group comprising one or more carbon atoms and optionally one or more hetero atoms, and wherein in Formula II, Z1 and Z2 are, leaving groups, X is a reactive functional hydrocarbon group for subsequent ring closure, comprising one or more carbon atoms and a reactive functional group and having a chain of between 1 to 6 atoms between the carbon atom attached to the central carbon atom of formula II and the reactive functional group and R8 is hydrogen or a hydrocarbon substituent different from X making the central carbon atom of formula II a chiral centre in Formula III and wherein reactive functional group X can be or can be extended to be compound of formula IV which can be ring closed to produce the polycyclic component of formula V. More in particular, the invention relates to the preparation of mirtazapine precursors and mirtazapine preferably having a substantial enantiomeric excess.